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1. Introduction 
Therapy with radioiodine (I-131) has been used for patients with well-differentiated thyroid 
cancer such as papillary and follicular thyroid carcinoma to ablate normal thyroid tissue or 
to treat metastatic lesions. The improvement of survival rates and decrease of recurrence 
rates after I-131 therapy has been documented by retrospective studies (Mazzaferri & 
Jhiang, 1994; Samaan et al., 1992). Even those patients categorized as low risk also had 
significantly lower recurrence and death rates after they received I-131 (Dietlein et al., 2005). 
Diagnostic I-123 or I-131 whole body scan (DxWBS) can be performed to detect persistent 
disease before radioiodine therapy. The post-therapeutic I-131 whole body scan (RxWBS) 
can be done after administration of therapeutic dose of I-131. 
1.1 Rationale of RxWBS 
The purpose of RxWBS is for detection and localization or exclusion of functioning thyroid 
remnants, persistent or recurrent local disease or distant metastasis in patients receiving I-
131 therapy (Luster et al., 2008). There are several reports regarding the higher detection 
ability of RxWBS than DxWBS. Therefore, the disease stage also can be changed after 
RxWBS. Fatourechi et al. reported that 13% of 117 patients of thyroid papillary cancer 
demonstrated abnormal foci on RxWBS, which were not seen on DxWBS (111 MBq (3 mCi), 
I-131) (Fatourechi et al., 2000). They also reported that RxWBS changed management 
strategy in 9% of 81 patients. Souza Rosario et al. reported that RxWBS on first ablation 
changed the disease stage in 8.3% of the patients and therapeutic approach in another 15% 
among total 106 patients (Souza Rosario et al., 2004). They also reported that RxWBS 
provided clinically relevant information for 26% of patients with 1 previous ablation. In 
their report, even when excluding cases whose lesions were known before scanning, the 
therapeutic approach was influenced by RxWBS in 15.6% of the patients.  
There are also several reports regarding comparison of I-123 DxWBS and RxWBS. In the 
retrospective study by Donahue et al., they reported that RxWBS could find more lesions in 
18% of 108 patients and clinical upstaging occurred in 10% of patients compared with 
DxWBS (I-123) (Donahue et al., 2008). In a study by Alzahrani et al., they showed 209 pairs 
of 238 pairs of RxWBS and DxWBS (I-123) were concordant (87.8% concordance rate) 
(Alzahrani et al., 2001). They also revealed that there were 29 discordant pairs, 13 RxWBS 
(5.5%) demonstrated additional foci of uptake at sites that were already positive on DxWBS  
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Fig. 1. Detection of metastatic lymph nodes on RxWBS, not on DxWBS. A 53-year-old 
woman with papillary thyroid cancer who underwent total thyroidectomy with left lateral 
neck dissection. A. I-123 DxWBS reveals a focal uptake in the anterior neck, suggesting 
remnant thyroid tissues in the thyroid bed. B. On RxWBS obtained 2 days after 
administration of 6.66 GBq (180 mCi) I-131, several focal hot uptake are noted in her left 
lateral neck and right highest mediastinal area. Neck ultrasonography revealed (image not 
shown) lesions suspicious of metastatic lymph nodes.  
(I-123). Distant metastasis of thyroid cancer is not extremely rare. There have been studies 
reported the distant metastasis was found in 7-23% (Casara et al., 1991; Cooper et al., 2009; 
Mazzaferri, 1986; Samaan et al., 1985; Schlumberger et al., 1986). Iwano et al. reported that 
the concordance rates between DxWBS (I-123) and RxWBS were high for thyroid bed and 
bone metastases (89% and 86%, respectively), while they were low for lymph node and lung 
metastases on RxWBS (61% and 39%, respectively) (Iwano et al., 2009).  
There are several reasons of performing RxWBS. 
a. Metastasis is not extremely rare in thyroid cancer. 
b. Presence of distant metastasis can change treatment strategies. 
c. RxWBS has better detection performances of detecting remnant or metastatic lesions 
than DxWBS. 
d. Performing scan after therapy does not require additional radiation exposure, like other 
radiologic evaluation. 
2. Protocols of RxWBS  
2.1 Imaging protocol  
2.1.1 Gamma camera or SPECT 
The efficacy of a system for imaging I-131 is dependent on the thickness of the crystal of 
camera and the collimator (Mazzaferri, 1986). I-131 whole body scan was usually done  
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Fig. 2. Multiple pulmonary metastases detected on RxWBS which were invisible on DxWBS. 
A 54-year-old woman who underwent total thyroidectomy for papillary thyroid cancer. A, I-
123 DxWBS shows several hot uptake in the anterior neck and upper mediastinum. B, On 
RxWBS obtained 3 days after the administration of 7.4 GBq (200 mCi) I-131, multiple 
metastatic lesions are newly detected in both the lung fields. 
using a large field of view gamma camera with a medium-energy, parallel-hole collimator, 
and the photo peak was 364 KeV with a 20% window. Continuous acquisition mode can be 
used with a scanning ratio of 9 - 13 cm/s with a 512 x 512 or 1,024 × 256 matrix. Anterior 
and posterior views of the whole body can be obtained simultaneously. Spot views of 
suspected sites of metastasis can be done additionally using a 256 × 256 matrix for a total of 
500,000 counts. Additional image such as scanning after drinking a glass of water to wash 
out physiologic uptake in the esophagus is sometimes needed (Figure 3).  
 
 
Fig. 3. Physiologic retention of I-131 in the esophagus. The physiologic I-131 retention 
(arrow) in the esophagus on RxWBS obtained after administration of 3.7 GBq (100 mCi) I-
131 (A). It disappeared after drinking a glass of water (B). 
www.intechopen.com
 12 Chapters on Nuclear Medicine 
 
234 
2.1.2 SPECT/CT   
Whole body imaging with SPECT/CT requires long scan time. Therefore, SPECT/CT is 
usually performed for specific site after whole body scan. The field of view (FOV) of 
SPECT/CT is usually determined by nuclear medicine physicians based on the planar image 
findings. So far, many companies have their models of SPECT/CT. This is the one of the 
usual protocol of SPECT/CT (Infinia Hawkeye 4) of our institution. First, emission SPECT 
images are acquired with counts from the 10% energy window at 364 KeV, with a matrix 
size of 128 x 128. A total image of 64 frames is acquired over 360˚ with an acquisition time of 
30 s/frame, angular step of 6˚, and zooming factor of 1. After SPECT acquisition, a CT scan 
is acquired with a low-dose, helical CT scanner. The CT parameters are 140 KeV and 5 mAs, 
and no intravenous iodinated contrast is administered. The CT data are used for attenuation 
correction. The Images are reconstructed with a conventional iterative algorithm, ordered 
subset expectation maximization (OSEM). A workstation providing multiplanar reformatted 
images are used for image display and analysis.  
2.2 Imaging timing of RxWBS 
Radioiodine is excreted slowly in hypothyroid patients, especially if they have been on a low 
iodine diet (Dietlein et al., 2005). Therefore, decreasing background activity is important for 
visualizing small metastases or remnant thyroid tissue. However, current guidelines for I-131 
therapy differ in their recommendations for the optimal time of the RxWBS ranging from 48 – 
72 hours (Becker et al., 1996; Luster et al., 2008) to 2 – 10 days (Cooper et al., 2009). Also, there 
is a lot of discrepancy in the published literature regarding the optimal timing of RxWBS 
(Cholewinski et al., 2000; Chong et al., 2010; Durante et al., 2006; Hindie et al., 2003; Hung et 
al., 2009; Khan et al., 1994; Nemec et al., 1979). So far, several studies were done for evaluating 
efficacy or accuracy of RxWBS which was done at different timing after high-dose I-131 
therapy. Khan et al. conducted scans at 2 days and 7 days post-therapy after 3.7–5.6 GBq of I-
131 administration (Khan et al., 1994). They reported a higher sensitivity for detection of 
iodine-avid tissue on RxWBS 7 days post-therapy than earlier RxWBS. Hung et al. analyzed 
RxWBS at three different time points (first scan performed 3–4 days, second scan 5–6 days, and 
third scan 10–11 days after I-131 therapy) (Hung et al., 2009). They retrospectively analyzed 
239 patients’ scans. Twenty-eight percent of lymph node metastases, 17% of lung metastases, 
and 16% of bone metastases were missed on the late images on 10-11th day. On the other 
hand, only 5% of the remnants were missed. The ratio of early washout was different between 
remnants and metastatic lesions. Chong et al. conducted RxWBS on the third and seventh days 
after I-131 therapy in 60 cases from 52 patients with lung or bone metastases of thyroid cancer 
(Chong et al., 2010). They showed that 22% of lung metastases and 33% of bone metastases 
that were not shown on the third day scan were detected on the seventh day scan (Figure 4 
and 5). Lee et al. conducted RxWBS on the third and tenth day after I-131 therapy in 81 
patients (Lee et al., 2011). They reported that the I-131 avid lesions on the early scan were more 
easily detected by visual analysis and had higher uptake ratios than those on the delayed scan. 
The optimal timing for RxWBS is still needed to be clarified.  
2.3 Medication and diet after administration of therapeutic dose of I-131  
Published guideline for I-131 therapy recommend that low-iodine diet, when possible, <50 
μg/day, starting 1-2 weeks prior to radioiodine administration is recommended (Cooper et al., 
2009; Luster et al., 2008). However, the duration of this low-iodine diet varies. Usually, regular 
diet can be started after the treatment. Information about low-iodine diet can be obtained at 
Thyroid Cancer Survivors Association website, http://www.thyca.org/rai.htm#diet.  
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Fig. 4. Diffuse pulmonary metastases. The metastatic uptake is not seen on I-123 DxWBS (A) 
and early RxWBS (on the third day after therapy) (B). It only appears on the RxWBS which 
was performed on the seventh day after the administration of 7.4 GBq (200 mCi ) I-131 (C).  
 
 
Fig. 5. Multiple osseous metastases. The metastatic lesion in the upper thoracic vertebra 
(arrow) is only visible on the RxWBS obtained seventh day after administration of 7.4 GBq 
(200 mCi) I-131 (B). These lesion is not visible on RxWBS obtained third day after therapy 
(A) or Tc-99m HDP WBS (C).  
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Thyroid hormone replacement may be resumed on the second or third day after therapy 
(Cooper et al., 2009; Luster et al., 2008).  
3. Findings of RxWBS  
The following data are needed to be reported: the name of patient, ID, age, the date of I-131 
therapy, I-131 dose, date of RxWBS. When it is available, the serum level of thyroglobulin, 
thyroid stimulating hormone and anti-thyroglobulin antibody are to be reported. The sites 
of significant I-131 uptake are needed to be mentioned.  
3.1 False positive RxWBS 
False positive RxWBS occurs for nonthyroidal I-131 concentration, including external 
contamination by the saliva, nasal secretions and sweat containing I-131, internal 
contamination through nasopharyngeal secretion, as well as physiologic uptake in 
nonthyroidal tissue such as the choroid plexus, salivary glands, gastric mucosa, and urinary 
tract. Carliscle et al. summarized false positive findings (Carlisle et al., 2003). I-131 uptake 
can be seen in the nose, salivary glands, mouth, thyroid bed, lactating breast, liver, gall 
bladder, stomach, esophagus and sweat (Figure 6). Physiologic uptake of I-131 in the 
salivary glands, nasal mucosa, gastric mucosa, colon, mammary glands and choroid plexus 
is due to the NIS presence in these tissues (Carlisle et al., 2003; Riedel et al., 2001). Thymic 
uptake is rare, there is a report that the incidence of thymic uptake was 1-1.2% of cases 
(Davidson & McDougall, 2000) (Figure 7).  
 
 
Fig. 6. Diffuse perspiration. (A) On the RxWBS obtained on the third day after I-131 therapy 
with 3.7 GBq (100 mCi), mild perspiration is noted in both the axillae. (B) On the RxWBS 
obtained on the seventh day after I-131 therapy, diffuse perspiration is present in both the 
axillae, chest, upper arms and hands.  
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Fig. 7. Thymic uptake. A 12-year-old girl underwent therapy with 3.7 GBq (100 mCi) I-131. 
RxWBS were obtaind on the third day (A) and seventh day (B) after therapy. Hot uptakes 
are seen in the right lower neck and upper chest. I-131 SPECT/CT (C) and F-18 FDG 
PET/CT images (D) confirmed I-131 uptake in the upper chest to be physiologic uptake in 
the thymus. 
Diffuse hepatic uptake of I-131 is rarely found due to occult hepatic metastases but more 
commonly due to the hepatic de-ionization and conjugation of I-131 which was not 
incorporated into the thyroid hormone (Carlisle et al., 2003). Chung et al. investigated 
hepatic uptake on DxWBS or RxWBS. They analyzed scans of 399 patients. They reported 
that hepatic uptake is more often when higher dose of I-131 was administered. They also 
reported that the more uptakes appeared in the residual thyroid, the more it appeared in the 
liver. However, they found that 15 patients showed diffuse hepatic uptake without uptake 
by the remnant thyroid or metastatic lesion. They followed these patients and metastatic 
lesions were found in 7 of 15 patients. So, they insisted that diffuse liver uptake indicated 
functioning thyroid remnant or metastasis (Chung et al., 1997) (Figure 8).  
There are some reports I-131 false positive uptake in other pathologic condition unrelated to 
thyroid cancer: tracheostomy site, bronchiectasis, pulmonary inflammatory disease, pleural 
effusion, salivary gland tumor, some other carcinoma such as adenocarcinoma, squamous 
carcinoma, Barrett’s esophagus, Meckel’s diverticulum (Ain & Shih, 1994; Berquist et al., 
1975; Caplan et al., 1987; Carlisle et al., 2003; Fernandez-Ulloa et al., 1976; Hoschl et al., 1988; 
Misaki et al., 1994; Mitchell et al., 2000; Muratet & Giraud, 1996), and so on. (Figure 9) 
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Fig. 8. Diffuse hepatic uptake. A 59-year-old female underwent I-131 therapy with 370 MBq 
(100 mCi) after total thyroidectomy. On the RxWBS obtained on the third day after therapy, 
mild focal uptakes in the anterior neck and right lower anterior neck are shown (A). On the 
RxWBS obtained on the seventh day after therapy, diffuse hepatic uptake appears in 
addition to the cervical uptakes (B).  
 
 
Fig. 9. I-131 accumulation in the benign pulmonary disease. A 51-year-old female 
underwent RxWBS on the third day (A) and the seventh day (B) after the administration of 
6.66 GBq I-131. Besides the hot uptake in the neck, slightly increased, focal, linear uptake 
(arrows on A and B) is shown. On SPECT/CT (C), it is on the medial segment of the right 
middle lobe. Chest CT (D) shows peribronchial cicatrical consolidation and adhesive 
atelectasis containing mild traction bronchiectatic change in this lesion.  
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3.2 Diagnostic value of RxWBS 
The visualizing functioning metastasis as well as remnant thyroid tissue is related to the 
dose of I-131. Waxman et al. reported that more lesions were detected when the activity 
administered was increased from 74 to 370 MBq (2 to 10 mCi) and when even higher yields 
at 1,110 to 3,700 MBq (30 to 100 mCi) (Waxman et al., 1981). Spies et al. reported that with 
higher therapeutic dose, RxWBS demonstrated additional findings or more accurate 
localization compared with a diagnostic dose of 185 MBq (5 mCi) in 46% of cases (Spies et 
al., 1989).  
The diagnostic accuracy of RxWBS is also related with the time interval from the date of 
administration of I-131 and that of scanning. Khan et al. and Chong et al. reported that 
earlier scanning might miss the lesions and the effectiveness of the delayed scan on the 
seventh day from the administration of I-131 (Khan S et al., 1994). Khan et al. performed 
RxWBS on the second day and seventh day post-therapy (Khan et al., 1994). They reported 
that the seventh day scan is more sensitive than third day scan. Chong et al. reported that 
22% of lung metastasis and 33% of bone metastases that were not shown on the third day 
scan, though they were detected on the seventh day scan (Chong et al., 2010) (Figure 10).  
 
 
Fig. 10. Vertebral metastasis mimicking remnant thyroid tissue. A 61-year-old female 
underwent RxWBS after administration of 7.4 GBq (200 mCi) I-131. RxWBS shows multiple 
uptakes in the abdomen and right pelvic area suggesting distant metastases. Focal uptake in 
the anterior neck was supposed to be usual remnant thyroid tissue. However, on additional 
SPECT/CT (B, C), the uptake is detected in the cervical vertebra (C5), not in the 
thyroidectomy site. SPECT/CT also reveals I-131 uptake on thelumbar vertebra (L3, D) and 
right iliac bone (E). 
www.intechopen.com
 12 Chapters on Nuclear Medicine 
 
240 
Hung et al. conducted different protocol, RxWBS on the third to fourth day, fifth to sixth 
day and tenth to eleventh day post-therapy (Hung et al., 2009). They reported that there is a 
trend of decreasing visualization of I-131 uptake in sequential images and that 17% of lung 
metastasis and 16% of bone metastases were missed on the tenth to eleventh day scans. Lee 
et al. conducted RxWBS on the third and tenth day post-therapy (Lee et al., 2011). They also 
reported significant reduction in visual analysis scores and uptake ratios of I-131 avid 
lesions on the delayed RxWBS. 
In addition, diagnostic accuracy of RxWBS is related to the past-history of previous I-131 
therapy. Oh et al. reported the sensitivity of RxWBS in detecting distant metastasis after first 
I-131 therapy is 75% (Oh et al., 2011). In contrast, in patients with history of multiple 
radioiodine therapy, sensitivity of RxWBS in detecting distant metastasis is only 35%. The 
sensitivity of RxWBS and SPECT/CT is reported to be similar. However, the specificity of 
RxWBS is lower than SPECT/CT (Table 1). The sensitivity of FDG PET/CT is lower than 
RxWBS in detecting distant metastasis and the specificity of FDG PET/CT is much higher 
than RxWBS or SPECT/CT.  
 
 Sens(%) Spec(%) DA(%) PPV(%) NPV(%) 
All patients (n=140)      
WBS 65 55 59 42 76 
SPECT/CT 65 95 85 86 85 
PET/CT 61 98 86 93 84 
Single therapy (n=101)      
WBS 90 56 63 35 6 
SPECT/CT 90 96 95 86 97 
PET/CT 48 100 89 100 88 
Multiple therapies (n=39)      
WBS 44 50 46 30 33 
SPECT/CT 44 86 59 85 46 
PET/CT 72 86 77 90 63 
Table 1. Diagnostic performance of WBS, SPECT/CT and PET/CT in detecting distant 
metastasis (patient-based analysis) (adapted and modified from Oh et al., 2011). 
Sens, Sensitivity; Spec, Specificity; DA, diagnostic accuracy; PPV, positive predictive value; 
NPV, negative predictive value 
Previous radioiodine scanning might be the reason of decreased sensitivity (Rawson et al., 
1951). Thyroid stunning has been reported as the temporary impairment of thyroid tissue 
after a 111 MBq (3 mCi) or greater diagnostic I-131 dose that decreases the final absorbed 
dose in ablative therapy. However, Rosario et al. reported that diagnostic scanning using a 
185 MBq (5 mCi) of I-131 dose does not interfere with uptake of the ablative dose or with 
treatment efficacy when ablation is performed within 72 hours (Rosario et al., 2005). Dam et 
al. reported that even though, stunning might occur but there was no significant difference 
in treatment success rates (Dam et al., 2004).  
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4. Other imaging modalities  
4.1 F-18 Fluorodeoxyglucose PET/CT 
Fluorodeoxyglucose (FDG) is a glucose analogue. This is taken into the cell and 
phosphorylated by the same mechanism as glucose. In thyroid cancer, “Flip-flop 
phenomenone” is reported (Feine et al., 1996; Khan N. et al., 2003). It means the 
alternating uptake pattern of I-131 and FDG by the differentiated papillary or follicular 
thyroid cancer, which thought to be related to the differentiation of tumor (Figure 11 and 
12). Bertagna et al. reported that F-18 FDG PET/CT positive results correlated with the 
serum thyroglobulin level in patients with negative I-131 whole body scan and high 
serum thyroglobulin level. They also reported that F-18 FDG PET/CT showed highest 
accuracy when the patient’s thyroglobulin level was higher than 21 ng/mL (Bertagna et 
al., 2009). In addition to that, they also revealed that the levothyroxine therapy regimen 
does not influence F-18 FDG PET/CT results. Yoshio et al. evaluated 55 cases with 
differentiated thyroid cancer with F-18 FDG PET/CT and reported that FDG-avid lesions 
are resistant to radioactive iodine therapy with or without I-131 uptake (Yoshio et al., 
2011). 
 
 
Fig. 11. Flip-flop phenomenone. A 44-year-old male underwent total thyroidectomy due to 
thyroid papillary carcinoma. I-123 DxWBS (A) shows several hot uptakes in the anterior 
neck, whereas F-18 FDG PET/CT (B) is negative.   
4.2 Tc-99m methoxyisobutylisonitrile (Tc-99m MIBI) 
Tc-99m MIBI, a lipophilic cationic molecules, was originally developed as a myocardial 
perfusion imaging agent. Today Tc-99m MIBI is also used for the study of many neoplastic 
diseases. The mechanism of Tc-99m MIBI accumulation in tumor has been reported to 
depend on the size of a tumor, the blood flow and the richness of mitochondria in the tumor  
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Fig. 12. Iodine negative and F-18 FDG PET positive case. A 65-year-old female underwent I-
123 DxWBS (A) and F-18 FDG PET/CT (B,C) for elevated serum thyroglobulin level (3 to 17 
ng/ml) after left modified radical lymph node dissection two years ago. I-123 DxWBS (A) 
does not show abnormal uptake. On F-18 FDG PET/CT (B), focal uptakes were shown in the 
left lateral neck (arrow). On axial view of fusion image (C), two hypermetabolic lesions were 
seen in the left cervical level II. Biopsy revealed recurred papillary carcinoma.  
cells (Moretti et al., 2005; Piwnica-Worms et al., 1994; Saggiorato et al., 2009). MIBI 
irreversibly passes into the mitochondria using the electrical gradient generated by a high 
negative inner transmembrane mitochondrial potential of malignant cells (Chernoff et al., 
1993; Moretti et al., 2005; Piwnica-Worms et al., 1994). Also, there is a report that TSH 
simulates both F-18 FDG PET and Tc-99m MIBI uptake in poorly differentiated papillary 
thyroid cancer in vitro experiment (Kim et al., 2009). Even though Tc-99m MIBI is inferior to 
I-131 scintigraphy in detecting I-131 avid lesions (Al Saleh et al., 2007), it can be applied for 
patients with elevated serum human thyroglobulin levels but negative I-131 whole body 
scan (Wu et al., 2003). However, there are several reports that F-18 FDG PET is more 
sensitive than Tc-99m MIBI SPECT in detecting metastatic cervical lymph node in 
differentiated thyroid cancer patients with elevated serum thyroglobulin level but negative 
I-131 whole body scan (Iwata et al., 2004; Wu et al., 2003) (Figure 13).  
4.3 Tc-99m tetrofosmin 
Tetrofosmin is a lipophilic phosphine useful for myocardial perfusion imaging. Significant 
uptake of Tc-99m tetrofosmin in the thyroid, breast and lung tumors is reported. Tc-99m 
tetrofosmin is useful in detection of thyroid metastatic disease, particularly when the tumor 
is not iodine avid. In addition, it does not require withdrawal of thyroid hormone 
suppression therapy (Sharma et al., 2007). Nishiyama et al. reported that detectability of 
thyroid cancer metastases using Tc-99m tetrofosmin was 79.4% and that Tc-99m tetrofosmin 
is more sensitive than I-131 for detection of differentiated thyroid cancer metastasis, 
particulary for regional lymph node (Nishiyama et al., 2000). Unal et al. reported different 
results that the sensitivities of Tl-201, Tc-99m tetrofosmin and I-131 in diagnosing distant 
metastases were comparable (0.85, 0.85, and 0.75, respectively) (Unal et al., 1998). 
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Fig. 13. I-131, Tc-99m MIBI and F-18 FDG images. A 62-year-old woman with metastatic 
papillary thyroid cancer to the left proximal humerus, clavicle and sternum underwent I-131 
therapy with 7.4 GBq (200 mCi). Her serum thyroglobulin level was 260 ng/mL. I-131 
RxWBS (A) shows focal hot uptakes in the left clavicle and huemrus. On Tc-99m MIBI WBS, 
irregular hot uptakes are detected in the sternal area and faint uptake in the left clavicle (B). 
F-18 FDG PET/CT (C-E) shows multiple hypermetabolic lesions in the sternum, both hilar 
lymph nodes and lungs.   
4.4 Thallium-201 
Thallium-201 (Tl-201) is a monovalemt cationic radioisotope listed in same group with 
gallium in the periodic table. The membrane permeability for Tl-201 is almost equal to that 
for potassium (Elgazzar et al., 1993). It is suggested that intracellular accumulation of 
thallous ions is due to the transmembrane electropotential gradient (Mullins & Moore, 
1960). The primary role of Tl-201 in nuclear medicine is for imaging of myocardial perfusion 
and viability (Pauwels et al., 1998). Also, Tl-201 chloride has affinity for various malignant 
tumors, although it is not specific for malignant tumor (Senga et al., 1982). Uptake of Tl-201 
in tumor seems to be determined by blood flow, grade of malignancy, viability of tumor 
cells and tumor necrosis (Pauwels et al., 1998). There are several reports regarding Tl-201 
and thyroid cancer. Shiga et al. compared FDG PET with I-131 and Tl-201 scintigraphy and 
reported that FDG uptake was concordant with I-131 in 38% and with Tl-201 uptake in 94% 
(Shiga et al., 2001). Senga et al. reported that when tumor showed a positive scan with Tl-
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201 chloride but negative results using Ga-67 citrate, it was differentiated thyroid carcinoma 
or poorly differentiated adenoma (Senga et al., 1982). Carril et al. analyzed Tl-201 and I-131 
in ablated thyroid cancer patients. They reported that the sensitivity and specificity were 
94% and 96% for Tl-201 and 29% and 100% for I-131 (Carril et al., 1997). Nakada et al. 
reported that Tl-201 uptake correlated well with the proliferating cell nuclear antigen index, 
which represents proliferative activity (Nakada et al., 1999).  
4.5 I-124 PET/CT 
I-124 is a positron emitter with a half-life of 4.18 days, produced by a cyclotron. It can be 
used to directly image thyroid cancer using PET scanner. Van Nostrand et al. compared I-
124 PET with I-131 DxWBS in detecting residual thyroid tissue and/or metastatic lesion. 
They reported that I-124 PET identified as many as 50% more foci of radioiodine uptake 
suggestive of additional residual thyroid tissue and/or metastasis (Van Nostrand et al., 
2010). They suggest that I-124 PET produced superior results because the PET scanner 
provides images with reduced background noise and enhanced spatial and contrast 
resolution compared with I-131 DxWBS. The longer half-life of I-124 is useful for dose 
monitoring over an extended time period (Surti et al., 2009). It can be also used for lesion-
specific dosimetry. I-131 mean absorbed dose distributions can be calculated from serial I-
124 PET image (Erdi et al., 1999; Larson & Robbins, 2002). 
5. Conclusion 
The I-123 DxWBS or I-131 DxWBS is sensitive and specific for treatable remnant or 
metastatic lesion. About 25% of RxWBS detect lesions missed by DxWBS. For this reason, 
following administration of a therapeutic I-131 dose, RxWBS should always be performed in 
patients with well differentiated thyroid cancer. The timing of RxWBS is currently still 
controversial. Based on several studies, the timing of post-therapeutic I-131 WBS is within 
5th to 10th day, especially more opportune around 7th day after therapy. I-131 WBS with 
SPECT/CT may be the highly tailored approach for assessing distant metastatic lesions in 
patients who received a radioiodine therapy if SPECT/CT is available. RxWBS is especially 
likely to provide the useful information when DxWBSs are negative and the serum 
thyroglobulin levels are elevated. Other imaging modalities including F-18 FDG PET/CT is 
useful in detecting remnant thyroid tissues or metastatic thyroid cancer in patient with the 
elevated serum thyroglobulin level and negative iodine images. I-124 can be also useful in 
detection of the lesion and evaluation of lesional and whole-body dosimetry in patients with 
well-differentiated thyroid cancer. 
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